A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
PHASE3
This is a Phase 3, randomized, double-blind, placebo-controlled multicenter...
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
PHASE3
The purpose of this study was to evaluate the safety and efficacy of ociper...
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
PHASE3
This is a phase 3, randomized, double-blind, placebo-controlled study to co...
Status
Completed
Location
Cancer Hospital Chinese Academy of Medical Sciences
Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
PHASE2
Patients diagnosed with locally advanced esophageal squamous cell carcinoma...
Status
Recruiting
Location
Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)